Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept

References

• U.S. Food and Drug Administration (FDA). International Conference on Harmonization (ICH) Guideline. E8: General considerations for clinical trials. Federal Register 1997;62: 66113–19.
   Google Scholar
• Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008;7:818–26.
   PubMed Web of Science ®Google Scholar
• Shih C, Berliner E. Diffusion of new technology and payment policies: coronary stents. Health Aff (Millwood) 2008;27:1566–76.
   PubMed Web of Science ®Google Scholar
• Avorn J. Debate about funding comparative-effectiveness research. N Engl J Med 2009;360:1927–9.
   PubMed Web of Science ®Google Scholar
• Ray WA, Stein CM. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med 2006;354:194–201.
   PubMed Web of Science ®Google Scholar
• Wilensky GR. Developing a center for comparative effectiveness information. Health Aff (Millwood) 2006;25:w572–85.
   Web of Science ®Google Scholar
• van Luijn JC, Gribnau FW, Leufkens HG. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol 2007;63:159–62.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drug details on Enbrel. Available online at: www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed January 2009).
   Google Scholar
• O'Dell JR. Anticytokine therapy – a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999;340:310–12.
   PubMed Web of Science ®Google Scholar
• Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124–34.
   PubMed Web of Science ®Google Scholar
• Current Controlled Trials. ISRCTN Register. Available online at: www.controlled-trials.com (accessed January 2009).
   Google Scholar
• U.S. National Institute of Health. ClinicalTrials.gov. Available online at: www.ClinicalTrials.gov (accessed January 2009).
   Google Scholar
• The European Medicines Agency. European Public Assessment Report: Enbrel®. Available online at: www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm (accessed January 2009).
   Google Scholar
• Taylor GJ, Wainwright P. Open label extension studies: research or marketing? Br Med J 2005;331:572–4.
   PubMed Web of Science ®Google Scholar
• Wainwright P. Consent to open label extension studies: some ethical issues. J Med Ethics 2002;28:373–6.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763–9.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478–86.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9.
   PubMed Web of Science ®Google Scholar
• Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224–6.
   PubMed Web of Science ®Google Scholar
• Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997;15:1052–62.
   PubMed Web of Science ®Google Scholar
• Fisher CJJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697–702.
   PubMed Web of Science ®Google Scholar
• Novak EJ, Blosch CM, Perkins JD, Davis CL, Barr D, McVicar JP, Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy. Transplantation 1998;66:1732–5.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586–93.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 2006;65:328–34.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443–50.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Landewe R, Bruyn GAW, Cantagrel A, Durez P, Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928–39.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385–90.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264–72.
   PubMed Web of Science ®Google Scholar
• Calin A, Dijkmans BAC, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594–600.
   PubMed Web of Science ®Google Scholar
• Davis JCJ, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230–6.
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JCJ. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349–56.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627–32.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–22.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241–51.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12.
   PubMed Web of Science ®Google Scholar
• The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351–61.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062–47.
   PubMed Web of Science ®Google Scholar
• Berman B, Patel JK, Perez OA, Viera MH, Amini S, Block S, Evaluating the tolerability and efficacy of etanercept compared to triamcinolone acetonide for the intralesional treatment of keloids. J Drugs Dermatol 2008;7:757–61.
   PubMed Web of Science ®Google Scholar
• Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006;166:902–8.
   PubMed Web of Science ®Google Scholar
• Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354:697–708.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008;7:940–6.
   PubMedGoogle Scholar
• Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135:1953–60.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044–7.
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 2007;22:724–9.
   PubMed Web of Science ®Google Scholar
• Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol 2005;26:903–7.
   PubMed Web of Science ®Google Scholar
• Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC, Griffith S, A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology 2007;107:99–105.
   PubMed Web of Science ®Google Scholar
• Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517–25.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437–40.
   PubMed Web of Science ®Google Scholar
• Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KMJ, A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007;110:1396–403.
   PubMed Web of Science ®Google Scholar
• Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463–72.
   PubMed Web of Science ®Google Scholar
• Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007;299:461–5.
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67:625–30.
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98–105.
   PubMed Web of Science ®Google Scholar
• Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006;24:1852–9.
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008;63:584–91.
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948–55.
   PubMed Web of Science ®Google Scholar
• Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005;99:1175–82.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088–94.
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240–5.
   PubMed Web of Science ®Google Scholar
• Schwarz EM, Campbell D, Totterman S, Boyd A, O'Keefe RJ, Looney RJ. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J Orthop Res 2003;21:1049–55.
   PubMed Web of Science ®Google Scholar
• Sha BE, Valdez H, Gelman RS, Landay AL, Agosti J, Mitsuyasu R, Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses 2002;18:661–5.
   PubMed Web of Science ®Google Scholar
• Smith JA, Thompson DJS, Whitcup SM, Suhler E, Clarke G, Smith S, A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18–23.
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Wallace CK, Young JB, Koerner MM, Thohan V, McRee S, The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy. Transplantation 2007;84:480–3.
   PubMed Web of Science ®Google Scholar
• Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315–22.
   PubMed Web of Science ®Google Scholar
• Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 2006;35:341–5.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008;158:1345–9.
   PubMed Web of Science ®Google Scholar
• Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006;65:1357–62.
   PubMed Web of Science ®Google Scholar
• De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. Panminerva Med 2006;48:129–35.
   PubMed Web of Science ®Google Scholar
• Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67(Suppl 3):iii2–25.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–79.
   PubMed Web of Science ®Google Scholar
• Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JWJ, Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64(Suppl 4):iv2–14.
   PubMedGoogle Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84.
   PubMed Web of Science ®Google Scholar
• Bijlsma JWJ, Weinblatt ME. Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis 2007;66:1409–10.
   PubMed Web of Science ®Google Scholar
• Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AHM, Schenk Y, ter Borg EJ, Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443–9.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii13–16.
   PubMed Web of Science ®Google Scholar
• Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46:1140–7.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol 2007;36:411–17.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50: 683–91.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care 2008;24:170–7.
   PubMed Web of Science ®Google Scholar
• Meyer RJ. Regulatory considerations for determining postmarketing study commitments. Clin Pharmacol Ther 2007;82:228–30.
   PubMed Web of Science ®Google Scholar
• Avorn J. Paying for drug approvals – who's using whom? N Engl J Med 2007;356:1697–700.
   PubMed Web of Science ®Google Scholar
• Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br Med J 2003;326:1167–70.
   PubMed Web of Science ®Google Scholar
• Congressional Budget Office. Research on the comparative effectiveness of medical treatments: issues and options for an expanded federal role. A CBO Paper, 2007. Available online at: www.cbo.gov/ftpdocs/88xx/doc8891/12-18-ComparativeEffectiveness.pdf (accessed May 2009).
   Google Scholar
• Agenzia Italiana del Farmaco. Independent research on drugs funded by the Italian Medicines Agency. Rome: AIFA, 2007 at (http://www.agenziafarmaco.it/sites/default/files/tipo_file0109. pdf (accessed May 2009).
   Google Scholar
• van der Heijde D, Landewe R, Klareskog L, Rodriguez-Valverde V, Settas L, Pedersen R, Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. Arthritis Rheum 2005;52:49–60.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412–19.
   PubMed Web of Science ®Google Scholar
• Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007;46: 999–1004.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53:887–9.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008; 11:400–7.
   PubMed Web of Science ®Google Scholar
• Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JEJ, Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231–40.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Finlay AY, Griffiths CEM, Woolley JM, Lalla D, Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153:1192–9.
   PubMed Web of Science ®Google Scholar
• Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128–39.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356–61.
   PubMed Web of Science ®Google Scholar
• van Riel PLCM, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008;67:1104–10.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med 2008;5:e67.
   PubMed Web of Science ®Google Scholar